Literature DB >> 22362299

Protease inhibitor monotherapy: what is its role?

Miriam Estébanez1, Jose R Arribas.   

Abstract

Protease inhibitor monotherapy has been shown to be effective in maintaining long-term viral suppression in a majority of patients. Withdrawal of nucleoside analogues can prevent long-term toxicity related to these drugs. Clinical trials have recently reported preliminary data on the beneficial effect of protease inhibitor monotherapy on body fat distribution and bone metabolism. Some of the uncertainties possibly associated with protease inhibitor monotherapy such as the increased risk of neurological events and a higher level of subclinical inflammation will be discussed in this review.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22362299     DOI: 10.1007/s11904-012-0112-1

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  39 in total

1.  Is lower serum 25-hydroxy vitamin D associated with efavirenz or the non-nucleoside reverse transcriptase inhibitor class?

Authors:  Christoph A Fux; Sandra Baumann; Hansjakob Furrer; Nicolas J Mueller
Journal:  AIDS       Date:  2011-03-27       Impact factor: 4.177

2.  Neuropsychiatric adverse events with ritonavir-boosted darunavir monotherapy in HIV-infected individuals: a randomised prospective study.

Authors:  Alan Winston; Gerd Fätkenheuer; Jose Arribas; Andrew Hill; Yvon van Delft; Christiane Moecklinghoff
Journal:  HIV Clin Trials       Date:  2010 May-Jun

3.  Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial.

Authors:  Jean-Luc Meynard; Vincent Bouteloup; Roland Landman; Philippe Bonnard; Vincent Baillat; André Cabie; Sami Kolta; Jacques Izopet; Anne-Marie Taburet; Patrick Mercie; Geneviève Chene; Pierre-Marie Girard
Journal:  J Antimicrob Chemother       Date:  2010-09-15       Impact factor: 5.790

Review 4.  Protease inhibitor monotherapy.

Authors:  Ignacio Pérez-Valero; Jose R Arribas
Journal:  Curr Opin Infect Dis       Date:  2011-02       Impact factor: 4.915

5.  Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-α2b plus ribavirin.

Authors:  Mayumi Ueyama; Mina Nakagawa; Naoya Sakamoto; Izumi Onozuka; Yusuke Funaoka; Takako Watanabe; Sayuri Nitta; Kei Kiyohashi; Akiko Kitazume; Miyako Murakawa; Yuki Nishimura-Sakurai; Yuko Sekine-Osajima; Yasuhiro Itsui; Seishin Azuma; Sei Kakinuma; Mamoru Watanabe
Journal:  Antivir Ther       Date:  2011

6.  Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.

Authors:  Christine Katlama; Marc A Valantin; Michele Algarte-Genin; Claudine Duvivier; Sidonie Lambert-Niclot; Pierre M Girard; Jean M Molina; Bruno Hoen; Sophie Pakianather; Gilles Peytavin; Anne G Marcelin; Philippe Flandre
Journal:  AIDS       Date:  2010-09-24       Impact factor: 4.177

7.  Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy.

Authors:  Constance Delaugerre; Philippe Flandre; Marie Laure Chaix; Jade Ghosn; François Raffi; Pierre Dellamonica; H Jaeger; D Shürmann; Isabelle Cohen-Codar; Philippe Ngo Van; Michael Norton; Anne-Marie Taburet; Jean-François Delfraissy; Christine Rouzioux
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

8.  Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.

Authors:  Jean-François Delfraissy; Philippe Flandre; Constance Delaugerre; Jade Ghosn; Andrzej Horban; Pierre-Marie Girard; Michael Norton; Christine Rouzioux; Anne-Marie Taburet; Isabelle Cohen-Codar; Philippe Ngo Van; Jean-Pierre Chauvin
Journal:  AIDS       Date:  2008-01-30       Impact factor: 4.177

9.  Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system.

Authors:  Scott Letendre; Jennifer Marquie-Beck; Edmund Capparelli; Brookie Best; David Clifford; Ann C Collier; Benjamin B Gelman; Justin C McArthur; J Allen McCutchan; Susan Morgello; David Simpson; Igor Grant; Ronald J Ellis
Journal:  Arch Neurol       Date:  2008-01

10.  Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen.

Authors:  Todd T Brown; Grace A McComsey; Martin S King; Roula B Qaqish; Barry M Bernstein; Barbara A da Silva
Journal:  J Acquir Immune Defic Syndr       Date:  2009-08-15       Impact factor: 3.771

View more
  4 in total

1.  Identification of novel HIV 1--protease inhibitors: application of ligand and structure based pharmacophore mapping and virtual screening.

Authors:  Divya Yadav; Sarvesh Paliwal; Rakesh Yadav; Mahima Pal; Anubhuti Pandey
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

2.  Host-pathogen interactions of retroviruses.

Authors:  Abdul A Waheed; Abraham L Brass; Suryaram Gummuluru; Gilda Tachedjian
Journal:  Mol Biol Int       Date:  2012-10-24

3.  Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy.

Authors:  Ignacio Pérez-Valero; Alicia González-Baeza; Miriam Estébanez; María L Montes-Ramírez; Carmen Bayón; Federico Pulido; José I Bernardino; Francisco X Zamora; Susana Monge; Francisco Gaya; María Lagarde; Rafael Rubio; Asunción Hernando; Francisco Arnalich; José R Arribas
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

4.  Lopinavir/Ritonavir Impairs Physical Strength in Association with Reduced Igf1 Expression in Skeletal Muscle of Older Mice.

Authors:  Siu Wong; Shalender Bhasin; Carlo Serra; Yanan Yu; Lynn Deng; Wen Guo
Journal:  J AIDS Clin Res       Date:  2013-06-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.